Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Lyn Benson who wrote (25728)	9/23/1998 6:30:00 PM
From: Henry Niman	Respond to of 32384

Large Biotechs moved up again today (SI's group rose over 2%: techstocks.com and once again, LGND is near the top. Thus, this week the group has moved up over 8%. Of course LGND has moved up 37.45% this week: techstocks.com and LGNDW has moved up 68.75% techstocks.com

To: Lyn Benson who wrote (25728)	9/24/1998 12:45:00 AM
From: Webhead	Read Replies (1) \| Respond to of 32384

Hi Lyn, With today's action LGND's new P&F price objective moved up to (gulp) $19. Untill we get a higher base the "official" stop loss point would be $5 with the double bottom break (personally, I wouldn't wait that long!). I'll wave my hands a lot and say look for a pullback from resistance at $10.5-11 to $9 but there is certainly no guarantee of a pullback. I don't chart LGNDW (though I own it) because I feel that LGND is less subject to the wild volitility that often hits LGNDW (plus I only have so much time to hand chart). Ed

To: Lyn Benson who wrote (25728)	9/24/1998 9:55:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's the first part of the Bear Stearn's summary by David Molowa, Ethan T. Lovell & Alan Myers of LGND's presentation yesterday: "Yesterday, the management of Ligand provided an update to investors at the 11th Annual Bear Stearns Health Care Conference. It is clear that the fourth quarter is shaping up to be an extremely busy time for the company. We anticipate the following events will transpire during the course of the quarter. First, the company should receive FDA approval for Ontak for the treatment of late stage CTCL and launch the product. Second, Panretin Gel for the treatment of Kaposis Sarcoma will go before an FDA advisory panel in early November and should be approved and launched by year end. Third, the company may announce the outlicening of it five late stage products in Japan, the Far East, Latin America and other geographies to strong regional players in return for upfront licensing fees and royalties. Fourth, the company may file an NDA for Targretin Gel for the early stage CTCL. Last, the company may announce strategic initiatives that could provide non-equity derived cash." (Emphasis added).